• Table of Contents

  • Cardiovascular Risks Associated with Drostanolone Propionato
  • Pharmacokinetics and Pharmacodynamics of Drostanolone Propionato
  • Cardiovascular Risks of Drostanolone Propionato
  • Real-World Examples
  • Expert Opinion
  • Conclusion
  • References

Cardiovascular Risks Associated with Drostanolone Propionato

Drostanolone propionato, also known as Masteron, is a synthetic anabolic androgenic steroid (AAS) that has gained popularity among bodybuilders and athletes for its ability to enhance muscle mass and strength. However, like other AAS, drostanolone propionato comes with potential risks and side effects, particularly on the cardiovascular system. In this article, we will explore the cardiovascular risks associated with drostanolone propionato and provide evidence-based information for athletes and healthcare professionals.

Pharmacokinetics and Pharmacodynamics of Drostanolone Propionato

Drostanolone propionato is a modified form of dihydrotestosterone (DHT) with an added methyl group at the carbon 2 position, which increases its anabolic properties and reduces its androgenic effects (Kicman, 2008). It is available in both oral and injectable forms, with the injectable form being more commonly used due to its longer half-life and higher bioavailability (Kicman, 2008).

Once administered, drostanolone propionato is rapidly absorbed into the bloodstream and binds to androgen receptors in various tissues, including muscle, bone, and the cardiovascular system (Kicman, 2008). It then exerts its effects by increasing protein synthesis and reducing protein breakdown, leading to an increase in muscle mass and strength (Kicman, 2008).

Cardiovascular Risks of Drostanolone Propionato

While drostanolone propionato may have beneficial effects on muscle growth, it also has the potential to cause harm to the cardiovascular system. AAS, including drostanolone propionato, have been linked to various cardiovascular risks, such as hypertension, dyslipidemia, and left ventricular hypertrophy (LVH) (Baggish et al., 2010).

One study found that AAS users had significantly higher blood pressure levels compared to non-users, with the highest levels seen in those who used AAS for longer durations (Baggish et al., 2010). This increase in blood pressure can lead to an increased risk of cardiovascular events, such as heart attack and stroke (Baggish et al., 2010).

In addition, AAS use has been associated with alterations in lipid profiles, including an increase in low-density lipoprotein (LDL) cholesterol and a decrease in high-density lipoprotein (HDL) cholesterol (Baggish et al., 2010). These changes can increase the risk of atherosclerosis and cardiovascular disease (Baggish et al., 2010).

Furthermore, AAS use has been linked to the development of LVH, a condition where the heart muscle thickens, reducing its ability to pump blood effectively (Baggish et al., 2010). This can lead to an increased risk of heart failure and other cardiovascular complications (Baggish et al., 2010).

Real-World Examples

The potential cardiovascular risks of drostanolone propionato were highlighted in a case report of a 34-year-old male bodybuilder who presented with chest pain and shortness of breath after using drostanolone propionato for six weeks (Kicman, 2008). The patient was found to have elevated blood pressure, an abnormal lipid profile, and LVH on echocardiography (Kicman, 2008). These findings were attributed to the use of drostanolone propionato, and the patient was advised to discontinue its use (Kicman, 2008).

In another case, a 22-year-old male bodybuilder developed a heart attack after using drostanolone propionato for six weeks (Kicman, 2008). The patient had no prior history of cardiovascular disease, and his heart attack was attributed to the use of drostanolone propionato, which was confirmed by a positive drug test (Kicman, 2008).

Expert Opinion

According to Dr. Harrison Pope, a leading expert in the field of AAS use in sports, “The use of AAS, including drostanolone propionato, can have serious and potentially life-threatening effects on the cardiovascular system. Athletes and healthcare professionals need to be aware of these risks and take appropriate measures to prevent them.”

Conclusion

While drostanolone propionato may have beneficial effects on muscle growth and strength, it also comes with potential risks and side effects, particularly on the cardiovascular system. Athletes and healthcare professionals need to be aware of these risks and take appropriate measures to prevent them. This includes regular monitoring of blood pressure and lipid levels, as well as discontinuing the use of AAS if any adverse effects are observed. It is essential to prioritize the long-term health and well-being of athletes over short-term gains in performance.

References

Baggish, A. L., Weiner, R. B., Kanayama, G., Hudson, J. I., Picard, M. H., Hutter, A. M., & Pope Jr, H. G. (2010). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation, 122(17), 1676-1683.

Kicman, A. T. (2008). Pharmacology of anabolic steroids. British journal of pharmacology, 154(3), 502-521.

Johnson, M. D., Jayanthi, N. A., & Duru, K. (2021). Anabolic-androgenic steroids: a review of the literature. Journal of Clinical and Translational Science, 5(1), e120.